March 24, 2023
Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday aft... See more »
XBiotech: XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer
AUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nation...
Read full article »
March 24, 2023
HIT Consultant Media
23andMe, Novartis Launches Pilot for Lipoprotein(a) Education
What You Should Know: - In support of Lipoprotein(a) Awareness Day, 23andMe, a human genetics and bio... See more »
March 25, 2023
The Wall Street Journal
Regeneron, Sanofi Look for Billions From COPD Drug
The companies said Dupixent showed positive results in a late-stage study of current or former smoker... See more »
March 23, 2023BioPharma Dive
Sanofi, Regeneron surge as Dupixent scores in COPD trial
The two companies gained billions of dollars in market value after their antibody drug succeeded agai... See more »
March 24, 2023Pharmabiz
Dupixent demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
The primary and all key secondary endpoints were met in a phase 3 trial evaluating the investigationa... See more »
March 24, 2023
Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday aft... See more »
March 24, 2023
HIT Consultant Media
23andMe, Novartis Launches Pilot for Lipoprotein(a) Education
What You Should Know: - In support of Lipoprotein(a) Awareness Day, 23andMe, a human genetics and bio... See more »
March 25, 2023
The Wall Street Journal
Regeneron, Sanofi Look for Billions From COPD Drug
The companies said Dupixent showed positive results in a late-stage study of current or former smoker... See more »
March 23, 2023BioPharma Dive
Sanofi, Regeneron surge as Dupixent scores in COPD trial
The two companies gained billions of dollars in market value after their antibody drug succeeded agai... See more »
March 24, 2023Pharmabiz
Dupixent demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
The primary and all key secondary endpoints were met in a phase 3 trial evaluating the investigationa... See more »
XBiotech is a biopharmaceutical company that develops antibody therapies for inflammatory diseases and colorectal cancer.
Read more